Biocon Limited has announced the appointment of Shreehas Tambe as its Chief Executive Officer and Managing Director, effective 1 April 2026. This decision follows approvals from the Nomination & Remuneration Committee and the Board of Directors. Tambe, as the first CEO of the integrated Biocon, will lead the company’s combined platform spanning biosimilars and generics, enhancing its ability to operate at scale and compete in global markets.
Kedar Upadhye has also been appointed as the Chief Financial Officer of Biocon Limited. This leadership transition is part of the full integration of Biocon Biologics Limited as a wholly owned subsidiary of Biocon Limited, creating a simplified and unified corporate structure. The strengthened enterprise is well-positioned to lead in diabetes, obesity, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies.
Kiran Mazumdar-Shaw, Executive Chairperson of Biocon Limited, expressed confidence in Tambe’s leadership, citing his role in strategic milestones such as the acquisition and integration of the Viatris biosimilars business. Under Tambe’s leadership, Biocon Biologics has emerged as one of the world’s top five biosimilar companies, with a valuation of USD 5.5 billion.
Shreehas Tambe expressed his honour and privilege in leading Biocon at a pivotal moment, focusing on strengthening the company’s foundation, consolidating business, and accelerating sustainable growth. He acknowledged the trust and confidence placed in him by the Chairperson and the Board of Directors.
Tambe joined Biocon nearly three decades ago and has played a pivotal role in scaling multiple businesses globally. He has held various leadership roles, including CEO and Managing Director of Biocon Biologics, where he led the transformational acquisition of Viatris’ biosimilars business.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).